

Hannah L Turner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4667578/publications.pdf>

Version: 2024-02-01

49
papers

5,609
citations

136885

32
h-index

223716

46
g-index

60
all docs

60
docs citations

60
times ranked

8266
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7348-E7357.	3.3	944
2	Pre-fusion structure of a human coronavirus spike protein. Nature, 2016, 531, 118-121.	13.7	623
3	Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Scientific Reports, 2018, 8, 15701.	1.6	408
4	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science, 2020, 370, 1089-1094.	6.0	290
5	Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science, 2016, 351, 1078-1083.	6.0	194
6	A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell, 2019, 177, 1136-1152.e18.	13.5	177
7	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. Immunity, 2018, 49, 288-300.e8.	6.6	175
8	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	13.5	173
9	Engineered immunogen binding to alum adjuvant enhances humoral immunity. Nature Medicine, 2020, 26, 430-440.	15.2	172
10	Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science, 2018, 362, 598-602.	6.0	170
11	Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Cell, 2016, 164, 392-405.	13.5	160
12	Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell, 2021, 184, 1188-1200.e19.	13.5	154
13	Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. Journal of Infectious Diseases, 2018, 218, S612-S626.	1.9	146
14	Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell, 2017, 169, 878-890.e15.	13.5	145
15	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. Immunity, 2019, 51, 915-929.e7.	6.6	111
16	Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell, 2017, 169, 891-904.e15.	13.5	103
17	Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nature Microbiology, 2016, 1, 16128.	5.9	92
18	Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines. Cell Reports, 2020, 30, 3755-3765.e7.	2.9	81

#	ARTICLE	IF	CITATIONS
19	Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. <i>Cell Reports</i> , 2016, 15, 1514-1526.	2.9	80
20	Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. <i>Cell Reports</i> , 2018, 23, 90-99.	2.9	80
21	Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebola Virus Neutralization. <i>Immunity</i> , 2020, 52, 388-403.e12.	6.6	71
22	Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebola Virus. <i>Cell Reports</i> , 2017, 19, 413-424.	2.9	66
23	Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity. <i>Nature Communications</i> , 2018, 9, 877.	5.8	65
24	Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15194-15199.	3.3	65
25	Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. <i>Cell Reports</i> , 2019, 28, 3395-3405.e6.	2.9	63
26	Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebola Virus Glycoprotein. <i>Immunity</i> , 2018, 49, 363-374.e10.	6.6	61
27	Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits. <i>Journal of Virology</i> , 2020, 94, .	1.5	57
28	In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. <i>Nature Communications</i> , 2017, 8, 15371.	5.8	55
29	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <i>PLoS Pathogens</i> , 2020, 16, e1009089.	2.1	55
30	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. <i>PLoS Pathogens</i> , 2020, 16, e1008665.	2.1	52
31	Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. <i>Cell Host and Microbe</i> , 2019, 26, 729-738.e4.	5.1	51
32	Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. <i>Cell Host and Microbe</i> , 2019, 26, 715-728.e8.	5.1	49
33	Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins. <i>PLoS Pathogens</i> , 2021, 17, e1009282.	2.1	42
34	Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. <i>PLoS Biology</i> , 2019, 17, e3000139.	2.6	37
35	Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization. <i>Science Advances</i> , 2021, 7, .	4.7	37
36	Fluorescent Trimeric Hemagglutinins Reveal Multivalent Receptor Binding Properties. <i>Journal of Molecular Biology</i> , 2019, 431, 842-856.	2.0	36

#	ARTICLE	IF	CITATIONS
37	Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccination. <i>Cell Reports</i> , 2021, 34, 108682.	2.9	31
38	Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
39	HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite. <i>Science Advances</i> , 2020, 6, eaba0512.	4.7	18
40	HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates. <i>Journal of Virology</i> , 2017, 91, .	1.5	15
41	Anti-“influenza H7 human antibody targets antigenic site in hemagglutinin head domain interface. <i>Journal of Clinical Investigation</i> , 2020, 130, 4734-4739.	3.9	13
42	Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
43	Drivers of recombinant soluble influenza A virus hemagglutinin and neuraminidase expression in mammalian cells. <i>Protein Science</i> , 2020, 29, 1975-1982.	3.1	6
44	Prominent Neutralizing Antibody Response Targeting the Ebolavirus Glycoprotein Subunit Interface Elicited by Immunization. <i>Journal of Virology</i> , 2021, 95, .	1.5	6
45	Human antibody recognition of H7N9 influenza virus HA following natural infection. <i>JCI Insight</i> , 2021, 6, .	2.3	1
46	Title is missing!. , 2020, 16, e1008665.		0
47	Title is missing!. , 2020, 16, e1008665.		0
48	Title is missing!. , 2020, 16, e1008665.		0
49	Title is missing!. , 2020, 16, e1008665.		0